Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Mar 2014
Letter Case ReportsDrug hypersensitivity syndrome in a patient receiving vismodegib.
-
J. Am. Acad. Dermatol. · Feb 2014
Comparative StudySerum endocan levels as a marker of disease activity in patients with Behçet disease.
Endocan is a novel human endothelial cell-specific molecule. The central role of leukocytes and endothelial dysfunction in the development of Behçet disease (BD) led us to hypothesize that endocan might be a marker of this disease. ⋯ Circulating endocan may be a marker of BD activity.
-
J. Am. Acad. Dermatol. · Jan 2014
Multicenter Study Clinical TrialExpanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Vismodegib, a first-in-class Hedgehog pathway inhibitor, was US Food and Drug Administration (FDA) approved for advanced basal cell carcinomas (BCCs) based on a single, nonrandomized, phase-II trial. Consequently, additional clinical data are critical to confirm the efficacy and safety of vismodegib. ⋯ This study provides important clinical data supporting the efficacy and safety of vismodegib. Larger studies are underway to assess predictors of response and long-term outcomes.
-
J. Am. Acad. Dermatol. · Jan 2014
Compliance with pregnancy prevention measures during isotretinoin therapy.
Approximately 150 women annually become pregnant while taking isotretinoin despite participation in the iPLEDGE program. Noncompliance with the requirement to be abstinent or use 2 contraceptive methods may be a contributing factor. ⋯ Encouraging the use of highly effective, patient-independent contraception and limiting abstinence to women who have never been sexually active may further reduce the rate of isotretinoin-exposed pregnancies.